Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Key Points

• The association of mhc-i or mhc-ii with pfs and orr was examined in patients.
• Results indicate the potential significance of mhc-i or mhc-ii levels in predicting response rates.
• Utilizing an observational analysis approach, data were collected from patients treated with nivo and relatlimab.
• These findings support the need for further exploration of mhc biomarkers in advanced melanoma treatment.